Prognostic factors and risk assessment in chronic myelomonocytic leukemia: Validation study of the M.D. Anderson Prognostic Scoring System

Miloslav Beran, Sijin Wen, Yu Shen, Francesco Onida, Jaroslav Jelinek, Jorge Cortes, Francis Giles, Hagop Kantarjian

Research output: Contribution to journalArticle

Abstract

Chronic myelomonocytic leukemia continues to be a poorly understood disease, defined by clinical rather than biological features, with no consensus on optimal therapy. In the past, patients were often assessed for risk using scoring systems developed for other diseases, notably the International Prognostic Scoring System commonly used for myelodysplastic syndrome. The M.D. Anderson Prognostic Scoring System, using hemoglobin, absolute lymphocyte count, peripheral blood immature cells, and bone marrow blasts, was developed specifically for CMML; it was based on retrospective analysis of 213 patients. This report re-examines the validity of this scoring system based on follow-up of the initial cohort and prospectively examines its validity in 250 new patients. Both the original MDAPS system and a modified version derived from data of the initial cohort after extended follow-up (substituting lactate dehydrogenase for bone marrow blasts) effectively stratify both patient cohorts by survival and provide a useful risk assessment tool and additional guidance during treatment decisions.

Original languageEnglish (US)
Pages (from-to)1150-1160
Number of pages11
JournalLeukemia and Lymphoma
Volume48
Issue number6
DOIs
StatePublished - Jun 1 2007
Externally publishedYes

Fingerprint

Leukemia, Myelomonocytic, Chronic
Validation Studies
Bone Marrow
Myelodysplastic Syndromes
Lymphocyte Count
L-Lactate Dehydrogenase
Blood Cells
Hemoglobins
Survival
Therapeutics

Keywords

  • Chronic myelomonocytic leukemia
  • Risk assessment
  • Scoring system

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Prognostic factors and risk assessment in chronic myelomonocytic leukemia : Validation study of the M.D. Anderson Prognostic Scoring System. / Beran, Miloslav; Wen, Sijin; Shen, Yu; Onida, Francesco; Jelinek, Jaroslav; Cortes, Jorge; Giles, Francis; Kantarjian, Hagop.

In: Leukemia and Lymphoma, Vol. 48, No. 6, 01.06.2007, p. 1150-1160.

Research output: Contribution to journalArticle

Beran, Miloslav ; Wen, Sijin ; Shen, Yu ; Onida, Francesco ; Jelinek, Jaroslav ; Cortes, Jorge ; Giles, Francis ; Kantarjian, Hagop. / Prognostic factors and risk assessment in chronic myelomonocytic leukemia : Validation study of the M.D. Anderson Prognostic Scoring System. In: Leukemia and Lymphoma. 2007 ; Vol. 48, No. 6. pp. 1150-1160.
@article{70a1680b72e24699a92fac97fea33fd3,
title = "Prognostic factors and risk assessment in chronic myelomonocytic leukemia: Validation study of the M.D. Anderson Prognostic Scoring System",
abstract = "Chronic myelomonocytic leukemia continues to be a poorly understood disease, defined by clinical rather than biological features, with no consensus on optimal therapy. In the past, patients were often assessed for risk using scoring systems developed for other diseases, notably the International Prognostic Scoring System commonly used for myelodysplastic syndrome. The M.D. Anderson Prognostic Scoring System, using hemoglobin, absolute lymphocyte count, peripheral blood immature cells, and bone marrow blasts, was developed specifically for CMML; it was based on retrospective analysis of 213 patients. This report re-examines the validity of this scoring system based on follow-up of the initial cohort and prospectively examines its validity in 250 new patients. Both the original MDAPS system and a modified version derived from data of the initial cohort after extended follow-up (substituting lactate dehydrogenase for bone marrow blasts) effectively stratify both patient cohorts by survival and provide a useful risk assessment tool and additional guidance during treatment decisions.",
keywords = "Chronic myelomonocytic leukemia, Risk assessment, Scoring system",
author = "Miloslav Beran and Sijin Wen and Yu Shen and Francesco Onida and Jaroslav Jelinek and Jorge Cortes and Francis Giles and Hagop Kantarjian",
year = "2007",
month = "6",
day = "1",
doi = "10.1080/10428190701216386",
language = "English (US)",
volume = "48",
pages = "1150--1160",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Prognostic factors and risk assessment in chronic myelomonocytic leukemia

T2 - Validation study of the M.D. Anderson Prognostic Scoring System

AU - Beran, Miloslav

AU - Wen, Sijin

AU - Shen, Yu

AU - Onida, Francesco

AU - Jelinek, Jaroslav

AU - Cortes, Jorge

AU - Giles, Francis

AU - Kantarjian, Hagop

PY - 2007/6/1

Y1 - 2007/6/1

N2 - Chronic myelomonocytic leukemia continues to be a poorly understood disease, defined by clinical rather than biological features, with no consensus on optimal therapy. In the past, patients were often assessed for risk using scoring systems developed for other diseases, notably the International Prognostic Scoring System commonly used for myelodysplastic syndrome. The M.D. Anderson Prognostic Scoring System, using hemoglobin, absolute lymphocyte count, peripheral blood immature cells, and bone marrow blasts, was developed specifically for CMML; it was based on retrospective analysis of 213 patients. This report re-examines the validity of this scoring system based on follow-up of the initial cohort and prospectively examines its validity in 250 new patients. Both the original MDAPS system and a modified version derived from data of the initial cohort after extended follow-up (substituting lactate dehydrogenase for bone marrow blasts) effectively stratify both patient cohorts by survival and provide a useful risk assessment tool and additional guidance during treatment decisions.

AB - Chronic myelomonocytic leukemia continues to be a poorly understood disease, defined by clinical rather than biological features, with no consensus on optimal therapy. In the past, patients were often assessed for risk using scoring systems developed for other diseases, notably the International Prognostic Scoring System commonly used for myelodysplastic syndrome. The M.D. Anderson Prognostic Scoring System, using hemoglobin, absolute lymphocyte count, peripheral blood immature cells, and bone marrow blasts, was developed specifically for CMML; it was based on retrospective analysis of 213 patients. This report re-examines the validity of this scoring system based on follow-up of the initial cohort and prospectively examines its validity in 250 new patients. Both the original MDAPS system and a modified version derived from data of the initial cohort after extended follow-up (substituting lactate dehydrogenase for bone marrow blasts) effectively stratify both patient cohorts by survival and provide a useful risk assessment tool and additional guidance during treatment decisions.

KW - Chronic myelomonocytic leukemia

KW - Risk assessment

KW - Scoring system

UR - http://www.scopus.com/inward/record.url?scp=34347346041&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34347346041&partnerID=8YFLogxK

U2 - 10.1080/10428190701216386

DO - 10.1080/10428190701216386

M3 - Article

C2 - 17577778

AN - SCOPUS:34347346041

VL - 48

SP - 1150

EP - 1160

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 6

ER -